A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and infants is set to launch in the Democratic Republic of Congo (DRC). This research could expand ...

Elsevier, a leader in information and analytics, has announced its support for The Pistoia Alliance in promoting safe and responsible AI adoption in drug discovery. This effort aims to address key AI ...

Tedros Adhanom Ghebreyesus, WHO Director-General, commented: “The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it. WHO ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the UK Dementia Research Institute and Health Data Research UK and funded by ...

AstraZeneca’s Andrea Mugan shares her unique perspectives on patients, experience, change and challenges ...

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage in the UK’s medicines manufacturing ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

Study reveals potential new strategy for managing inflammatory bowel disease Celltrion has announced groundbreaking results from a two-year study on dose escalation of subcutaneous infliximab (CT-P13 ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...